SOURCE: Protherics PLC

January 03, 2007 09:27 ET

Protherics PLC - EGM Statement

Cheshire, UK -- (MARKET WIRE) -- January 3, 2007 --Not for release, publication or distribution, in whole or in part, in, into or from the United States, Canada, Australia and Japan

                        Protherics PLC

         Result of Extraordinary General Meeting ("EGM")
London, UK; Brentwood, TN, US; 3 January 2007 - Protherics PLC ('Protherics' or the 'Company'), the international biopharmaceutical company focused on critical care and cancer, announces that at the EGM of the Company held today all of the resolutions were duly passed by shareholders. The proxy figures for the resolutions are set out below and will shortly be displayed on the Company's website at
Resolution   Shares For    Shares     Shares Against Shares Marked As Poll
  Number                Discretionary                Votes Withheld/
                                                     Abstentions   Yes/No
   1.        158,811,415    774,873      8,402,468      392,086      No
   2.        158,808,392    780,753      8,399,611      392,086      No
   3.        158,760,297    812,541      8,403,286      404,718      No
   4.        154,857,145    814,117     12,168,680      540,900      No
Application has been made for 77,486,381 New Ordinary Shares (comprising 26,029,550 Cash Placing Shares, 32,685,994 Placing and Open Offer Shares, 3,093,638 Glenveigh Consideration Shares and, after adjusting for transaction expenses, 15,677,199 MacroMed Consideration Shares) to be admitted to the Official List and to trading on the London Stock Exchange's market for listed securities and it is expected that Admission will become effective and dealings will commence at 08.00am on 4 January 2007.

Completion of the Glenveigh Licence, the Cash Placing and the Placing and Open Offer is expected to take place tomorrow upon Admission and completion of the MacroMed Acquisition is expected to take place at 4.00pm London time (9am Utah time) tomorrow Thursday 4 January 2007.

Terms used in this announcement shall have the same meaning as those used in the Company's prospectus dated 7 December 2006, a copy of which includes, inter alia, the full text of the resolutions, and is available for inspection at the Document Viewing Facility of the Financial Services Authority at 25 The North Colonnade, Canary Wharf, London, E14 5HS.


For further information:

Andrew Heath, CEO                               +44 (0) 20 7246 9950
Barry Riley, CFO                                +44 (0) 1928 518 003
Julie Vickers, Company Secretary                +44 (0)1928 518010
Saul Komisar, President Protherics Inc           +1 615 327 1027

Or visit

Notes for Editors:

About Protherics

Protherics (LSE: PTI, NASDAQ: PTIL) is an integrated biopharmaceutical company focused on the development, manufacture and marketing of specialist products for critical care and oncology.

Protherics' strategy is to use the revenues generated from its marketed products to help fund the advancement of its development pipeline. With a proven track record, Protherics' goal is to develop and attract additional critical care and cancer products for its sales and marketing teams to distribute in the US and Europe.

The majority of the Company's sales revenues (GBP17.7m in the year ended 31 March 2006) are derived from two critical care products, CroFabTM (pit viper antivenom) and DigiFabTM (digoxin antidote) which were developed by Protherics and are sold, in the US, through Fougera Inc, a division of Altana AG.

Protherics potentially has two blockbuster opportunities in its critical care franchise. CytoFabTM, is being developed by AstraZeneca for the treatment of severe sepsis, and is expected to start an additional phase 2 study in 2007. In addition, subject to completion of the Cash Placing, the Company has agreed to in-license intellectual property from Glenveigh (a small private US based company) relating to the use of anti-digoxin polyclonal antibody fragments such as DigiFabTM and GSK's Digibind® in the treatment of pre-eclampsia and eclampsia. Glenveigh is currently undertaking a phase 2b study with Digibind® which Protherics expects to report in 2007.

Subject also to Admission, the MacroMed Acquisition increases Protherics cancer products in development to four. In addition, the Company is developing its Angiotensin Therapeutic Vaccine for the treatment of hypertension.

With headquarters in London, the Company has about 230 employees across its operations in the UK, US and Australia.

For further information visit:


This document contains forward-looking statements that involve risks and uncertainties, including with respect to completion of the Equity Fundraising, the Glenveigh Licence and the MacroMed Acquisition and anticipated development and clinical trials for product candidates. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, including the factors discussed in Protherics' Annual Report on Form 20-F and other reports filed from time to time with the U.S. Securities and Exchange Commission. We do not undertake to update any oral or written forward-looking statements that may be made by or on behalf of Protherics.

                      This information is provided by RNS
            The company news service from the London Stock Exchange